Last reviewed · How we verify
SOM230C
At a glance
| Generic name | SOM230C |
|---|---|
| Also known as | pasireotide LAR |
| Sponsor | Patrick Y. Wen, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Monthly SOM230C for Recurrent or Progressive Meningioma (PHASE2)
- Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma (PHASE2)
- Phase I Trial of Combination of FOLFIRI and SOM 230 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOM230C CI brief — competitive landscape report
- SOM230C updates RSS · CI watch RSS
- Patrick Y. Wen, MD portfolio CI